Posted by Michael Wonder on 05 Dec 2025
Lecanemab in early Alzheimer's disease: previously unpublished data show no additional benefit
1 December 2025 - Based on previously unpublished data, the IQWiG concludes that lecanemab offers no proven advantage over the existing standard of care in Germany.
Lecanemab has been available in Germany since September 2025 for the treatment of early Alzheimer's disease.
